Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has issued its preliminary financial results for the fourth quarter of 2025 and provided an outlook for 2026. The announcement was made on January 12.
The company indicated that its fourth-quarter revenue is expected to be approximately $69.8 million. This compares to $57.6 million reported for the same period in 2024. Gross product sales for the quarter are projected at $84.5 million.
These sales are driven by TAVALISSE net product sales of $45.6 million, GAVRETO net product sales of $10.2 million, and REZLIDHIA net product sales of $9.6 million.
For the full year 2025, Rigel anticipates revenue of about $294.3 million, an increase from the $179.3 million recorded in 2024. Looking forward, management projects total revenue for 2026 to be in the range of $275 million to $290 million.
Following the release, Wall Street responded positively. On January 13, Joseph Pantginis, an analyst at H.C. Wainwright, reiterated a Buy rating on Rigel's stock. He set a price target of $57.
Rigel Pharmaceuticals is a clinical-stage biotechnology company focused on developing targeted drugs in oncology and immunology. Its product portfolio includes Tavalisse, Fostamatinib, and R835.